For instance, Li et al. (2011) used a docking method to test 4,621 approved drugs from DrugBank against the crystal structure of MAPK14 to identify a potential anti-inflammatory drug for the treatment of chronic myeloid leukemia. This evidence concerns the gene MAPK14 and chronic myelogenous leukemia, BCR-ABL1 positive.